Value-Based Cancer Care Issues


February 2011, Vol 2, No 1

Healthcare Reform Boosted at ASH

Colin Gittens

Uncategorized

Orlando, FL—Healthcare reform offers a chance to correct course from an unsustainable financial path and offers many benefits, said Ezekiel J. Emanuel, MD, PhD, at a policy forum jointly hosted by the American Society of Hematology (ASH) and the European [ Read More ]

Weighing In on the Avastin Decision

Meeting Highlights

To assess the potential implications, further questions, and next steps concerning bevacizumab (Avastin) use in patients with metastatic breast cancer, we spoke with a number of key constituents as well as our own editorial board members. One important question evoked [ Read More ]

FDA Approves Denosumab for Cancer-Related Bone Injury Prevention

Uncategorized

Data from 3 double-blind, randomized clinical trials have informed the FDA’s decision to approve denosumab (Xgeva) for the prevention of skeletal-related events (SREs) including bone fractures and bone pain requiring radiation in patients with meta static cancer. Denosumab is a [ Read More ]

Iniparib Raises Hopes in Triple-Negative Breast Cancer

Uncategorized

A phase 2 study looking at the ad dition of iniparib to gemcitabine (Gemzar) and carboplatin (Paraplatin) in patients with metastatic triplenegative breast cancer has indicated dramatic improvements in progression- free survival (PFS) and overall survival (OS) with this therapy [ Read More ]

Greater Role for Trastuzumab in Smaller HER2-Positive Cancers?

Uncategorized

A point-of-view essay by 2 English physicians outlines the controversies inherent in treating patients with breast cancer with small (≤1 cm) HER2-positive tumors and the possible benefit that adjuvant trastuzumab (Herceptin) might offer (Lancet Oncol. 2010;11:1193-1199). Although the combination of [ Read More ]

Targeting Yearly Mammograms to At-Risk Patients Holds Promise

Uncategorized

Directing yearly mammography efforts to younger women with a familial history of breast cancer will likely prevent deaths, results of a new study show (Lancet Oncol. 2010;11: 1127-1134). English researchers enrolled a cohort of women at intermediate familial risk of [ Read More ]

Value of Tamoxifen, Long- Term Radiotherapy Confirmed in DCIS

Uncategorized

Enhanced screening efforts have increased the number of patients diagnosed with ductal carcinoma in situ (DCIS). Of the treatment options available, radiotherapy has previously been shown effective in reducing recurrences of in situ or invasive ipsilateral disease. New long-term results [ Read More ]

Newer Agents Show Promise in CML

Meeting Highlights

Orlando, FL—Two early trials of newer drugs that inhibit the BCRABL gene—ponatinib and nilotinib (Tasigna)—for treatment of chronic myelogenous leukemia (CML) demonstrate clinical promise in terms of early or significant clinical response, according to research presented at the 2010 annual [ Read More ]

Nonmedical Burden of DVT Is High

Debra Wood, RN

Meeting Highlights

Orlando, FL—The economic burden associated with deep-vein thrombosis (DVT) during the 2-year period after diagnosis is substantial—$5094 Canadi an—with most of the costs occurring in the first 4 months, and postthrombotic syndrome representing a significant predictor of higher cost. “It [ Read More ]

Conference Promises Valuable Perspectives

AVBCC Preview

The Association for Value-Based Cancer Care’s First Annual Stakeholder Integration Conference will be held in Philadelphia on March 29- 30, 2011 (see full agenda below). To help set the stage for this meeting, Value- Based Cancer Care (VBCC) interviewed Gary [ Read More ]

Implementing Clinical Pathways at an Oncology Practice

Uncategorized

To learn about implementing clinical pathways in an individual practice, VBCC spoke with Barry Russo, Chief Executive Officer, Center for Cancer and Blood Disorders, Fort Worth, TX. What was life like before pathways at your 18-physician practice? Prior to pathways, [ Read More ]

Radiation Oncology Pathways

Colin Gittens

Uncategorized

  Medical oncology pathways have arisen in the past several years as a means to standardize care, improve patient outcomes, and structure clinical/financial arrangements so that practices can more easily work with payers. That approach is now being attempted on [ Read More ]

Preventing Emesis Can Save Money

Wayne Kuznar

Meeting Highlights

Anaheim, CA—Assessing palonosetron use for the prevention of emesis associated with chemotherapy has the potential to differentiate appropriate and inappropriate use and can lead to cost-savings, said John P. Jezak, PharmD, a pharmacy practice resident at Dartmouth-Hitchcock Medical Cen – [ Read More ]